Off-Label Promotion Settlement Includes Optional Preclearance Process
This article was originally published in The Gray Sheet
Executive Summary
Amarin may submit up to two proposed communications annually to FDA about unapproved use of its triglyceride-lowering drug Vascepa, and the agency must respond with any concerns within 60 calendar days.
You may also be interested in...
How Should US FDA Navigate Thorny First Amendment Conundrums: Former Chief Counsels Offer Advice
Daniel Troy suggests FDA increase its investment in science of consumer understanding, while Richard Cooper recommends the "bully pulpit" approach to get industry's attention. A panel of former chief counsels stressed that the agency cannot continue to ignore First Amendment free speech issues.
FDA Guidance On Health Care Economic Data Is Coming In 2015
Agency originally said it would issue a draft guidance on industry’s interactions with formulary committees in 2014, but CDER Director Woodcock says “extremely contentious” issues have slowed progress.
Teva Calls In Sanofi To Turbocharge Its Place In Blockbuster TL1A Inflammation Race
Signing a deal worth up to $1.5bn, Teva is hoping Sanofi’s dominance in immunology via the mega-blockbuster Dupixent can help it compete with frontrunners Pfizer/Roivant and Merck & Co in a new anti-inflammatory space.